- Home
- YJ vs BTAI Comparison
YJ vs BTAI Comparison
Compare YJ & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YJ
- BTAI
- Stock Information
- Founded
- YJ 2015
- BTAI 2017
- Country
- YJ China
- BTAI United States
- Employees
- YJ N/A
- BTAI N/A
- Industry
- YJ Other Specialty Stores
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- YJ Consumer Discretionary
- BTAI Health Care
- Exchange
- YJ Nasdaq
- BTAI Nasdaq
- Market Cap
- YJ 8.4M
- BTAI 8.3M
- IPO Year
- YJ 2019
- BTAI 2018
- Fundamental
- Price
- YJ $2.09
- BTAI $1.84
- Analyst Decision
- YJ
- BTAI Buy
- Analyst Count
- YJ 0
- BTAI 5
- Target Price
- YJ N/A
- BTAI $34.60
- AVG Volume (30 Days)
- YJ 34.2K
- BTAI 294.8K
- Earning Date
- YJ 08-22-2025
- BTAI 08-05-2025
- Dividend Yield
- YJ N/A
- BTAI N/A
- EPS Growth
- YJ N/A
- BTAI N/A
- EPS
- YJ N/A
- BTAI N/A
- Revenue
- YJ $57,219,520.00
- BTAI $1,852,000.00
- Revenue This Year
- YJ N/A
- BTAI $5.03
- Revenue Next Year
- YJ N/A
- BTAI $291.01
- P/E Ratio
- YJ N/A
- BTAI N/A
- Revenue Growth
- YJ N/A
- BTAI 5.47
- 52 Week Low
- YJ $1.37
- BTAI $1.17
- 52 Week High
- YJ $3.16
- BTAI $23.04
- Technical
- Relative Strength Index (RSI)
- YJ 64.54
- BTAI 62.90
- Support Level
- YJ $1.65
- BTAI $1.59
- Resistance Level
- YJ $2.04
- BTAI $2.22
- Average True Range (ATR)
- YJ 0.11
- BTAI 0.21
- MACD
- YJ 0.02
- BTAI 0.04
- Stochastic Oscillator
- YJ 76.73
- BTAI 75.00
About YJ Yunji Inc. American Depository Shares
Yunji Inc is a social e-commerce platform in China that offers a membership-based model that leverages the power of social interaction. The company provides a host of selected commodities such as beauty and personal care, mobile phones and digital products, baby and maternal products, toys, fruits, and other fresh products. It has expanded to operate its business, including the marketplace, on a diverse range of sales channels and other platforms. Geographically, the firm operates in the PRC.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.